Pfizer made a 15% equity investment in Vivet Therapeutics with an exclusive option to acquire all remaining shares for up to euro 560 million ($635M total). Targets VTX-801, an AAV gene therapy for Wilson disease, plus Vivet's broader gene therapy pipeline.